Virilising ovarian tumors: a single center experience

in Endocrine Connections
Correspondence: Tushar Bandgar, Email:

Aims: Literature on virilising ovarian tumors (VOT) is limited to case reports and series reporting single pathological type. We have analyzed the clinical, hormonal, radiological, histological, management and outcome data of VOT.

Materials and methods: This retrospective study was conducted at a tertiary health care center from Western India. Consecutive patients with VOT presenting to our endocrine center between 2002 and 2017 were included.

Results: Our study included 13 patients of VOT, two of whom were postmenopausal. All patients in the reproductive age group had secondary amenorrhea except one who presented with primary amenorrhea. Modified F and G score (mFG) at presentation was 24±4.3 and all patients had severe hirsutism (mFG ≥ 15). Change in voice (n=11) and clitoromegaly (n=7) were the other most common virilising symptoms. Duration of symptoms varied from 4 to 48 months. Median serum total testosterone level at presentation was 5.6 ng/ml with severe hyperandrogenemia (serum testosterone ≥ 2 ng/ml) but unsuppressed gonadotropins in all patients. Transabdominal ultrasonography (TAS) detected VOT in all except one. Ten patients underwent unilateral salpingo-oophorectomy whereas three patients (peri- or postmenopausal) underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. Seven patients had Sertoli-Leydig cell tumor, three had steroid cell tumor and two had Leydig cell tumor and one had miscellaneous sex cord stromal tumor. All patients had normalization of serum testosterone after tumor excision.

Conclusions: Virilising ovarian tumors present with severe hyperandrogenism and hyperandrogenemia. Sertoli-Leydig cell tumor is the most common histological subtype. Surgery is the treatment of choice with good outcome.


An official journal of

European Society of Endocrinology Society for Endocrinology